Biosecurity and Medicines Notices




NEW ZEALAND GAZETTE, No. 15 — 16 FEBRUARY 2017

Notice of Intention to Incorporate Material By Reference—Biosecurity Documents (Notice No. MPI 724)

Peter Thomson, Director Plants Food and Environment for the Ministry for Primary Industries (MPI), acting under delegated authority from the Director-General of MPI, gives notice under section 142N(4) of the Biosecurity Act 1993 ("Act") that, under section 142M of the Act, some or all of the following material, in whole or in part, is proposed for incorporation by reference, in one or more Biosecurity Documents made under the Act:

  • ePest database, which sets out plant products and associated pests from importing countries.

The following address is:

a. Where comments on this proposal to incorporate material by reference are to be sent; and
b. where the material incorporated can be viewed free of charge.

Ministry for Primary Industries
Biosecurity and Environment
PO Box 2526
Wellington 6140

Any written comment must be received by the Ministry for Primary Industries no later than 10 working days after the date of notification in the New Zealand Gazette.

Consultation on this proposal to incorporate material by reference is in addition to the usual process for consultation on any biosecurity document under the Act.

Dated at Wellington this 8th day of February 2017.

PETER THOMSON, Director Plants Food and Environment, Ministry for Primary Industries.

2017-g0614

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product:
Blackmores Macu-Vision

Active Ingredients:
Ascorbic acid 250mg
Cupric oxide 1.25mg equivalent to copper 1mg
D-alpha-Tocopheryl acid succinate 165mg equivalent to vitamin E 200IU
Zinc oxide 49.8mg equivalent to zinc 40mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Blackmores (NZ) Limited

Manufacturer:
Catalent Australia Pty Limited, Melbourne, Australia

Product:
Descovy 200mg/10mg

Active Ingredients:
Emtricitabine 200mg
Tenofovir alafenamide fumarate 11.2mg equivalent to tenofovir alafenamide 10mg

Dosage Form:
Tablet

New Zealand Sponsor:
Gilead Sciences (NZ)

Manufacturer:
Patheon Inc, Mississauga, Canada

Product:
Descovy 200mg/25mg

Active Ingredients:
Emtricitabine 200mg
Tenofovir alafenamide fumarate 28mg equivalent to tenofovir alafenamide 25mg

Dosage Form:
Tablet

New Zealand Sponsor:
Gilead Sciences (NZ)

Manufacturer:
Patheon Inc, Mississauga, Canada

150



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2017, No 15





✨ LLM interpretation of page content

🌾 Notice of Intention to Incorporate Material By Reference—Biosecurity Documents

🌾 Primary Industries & Resources
8 February 2017
Biosecurity, Incorporation by Reference, ePest database, Consultation
  • Peter Thomson, Director Plants Food and Environment, Ministry for Primary Industries

🏥 Consent to the Distribution of New Medicines

🏥 Health & Social Welfare
Medicines, Distribution, Blackmores Macu-Vision, Descovy